Not only was it the largest Phase yet at the time, but Phase Three also contains both the climax and grand finale of the long ...

Immunome’s investigational oral therapy has slashed the risk of disease progression or death by 84% for patients with desmoid ...

Revolution Medicines, Inc. ($RVMD) announced an update on their ongoing clinical study. Study Overview Revolution Medicines, Inc. is running a ...

Zenas's strong balance sheet, with $301.6M in cash and runway into late 2026, supports aggressive late-stage pipeline ...

Altimmune has shared an update on the metabolic dysfunction-associated steatohepatitis (MASH) study that sank its stock in June. The 48-week readout linked the top dose of the GLP-1/glucagon dual ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The double-blind, randomized, placebo-controlled phase 3 ...

Over 230 patients screened and over 160 patients enrolled in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC)Enrollment exceeding expectations with strong clinical site and patient ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Use of alternative endpoints in phase 3 oncology trials ...

Research into clinical uses for psychedelics has proliferated in recent years, but despite the constant stream of "psychedelic renaissance" news, the vast majority of studies remain in early, ...

Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder ...